Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Popat

Showing results (51-60 of 82) with videos related to

Pageof 9
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 28, 2015
The National Lung Matrix Trial: translating the biology of stratification in advanced non-small-cell lung cancerG Middleton, L R Crack, S Popat, et al.
British Journal of Cancer|December 24, 2010
A prospective study of chemotherapy-induced febrile neutropenia in the South West London Cancer Network. Interpretation of study results in light of NCAG/NCEPOD findingsM Okera, S Chan, U Dernede, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 25, 2016
Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upS Novello, F Barlesi, R Califano, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 29, 2020
Correction to: "Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up"D Planchard, S Popat, K Kerr, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 5, 2018
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upD Planchard, S Popat, K Kerr, et al.
European Journal of Cancer (Oxford, England : 1990)|November 29, 2011
A phase II study of ¹⁸F-fluorodeoxyglucose PET-CT in non-small cell lung cancer patients receiving erlotinib (Tarceva); objective and symptomatic responses at 6 and 12 weeksM E R O'Brien, J S Myerson, J I G Coward, et al.
BMJ Open Respiratory Research|January 2, 2015
An unblinded, randomised phase II study of platinum-based chemotherapy with vitamin B12 and folic acid supplementation in the treatment of lung cancer with plasma homocysteine blood levels as a biomarker of severe neutropenic toxicityA R Minchom, K Saksornchai, J Bhosle, et al.
Lung Cancer (Amsterdam, Netherlands)|November 20, 2024
Lorlatinib-associated weight gain and dyslipidaemia: A retrospective analysis and implications for future careA John, D J McMahon, D Chauhan, et al.
Lung Cancer (Amsterdam, Netherlands)|April 3, 2024
Familial rare EGFR-mutant lung cancer syndrome: Review of literature and description of R776H familyL Gabriel, T McVeigh, S Macmahon, et al.
ESMO Open|June 30, 2023
Ramucirumab plus erlotinib versus placebo plus erlotinib in previously untreated EGFR-mutated metastatic non-small-cell lung cancer (RELAY): exploratory analysis of next-generation sequencing resultsE B Garon, M Reck, K Nishio, et al.
Pageof 9

Showing results (51-60 of 82) with videos related to

Sort By:
Pageof 9
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 28, 2015
The National Lung Matrix Trial: translating the biology of stratification in advanced non-small-cell lung cancerG Middleton, L R Crack, S Popat, et al.
British Journal of Cancer|December 24, 2010
A prospective study of chemotherapy-induced febrile neutropenia in the South West London Cancer Network. Interpretation of study results in light of NCAG/NCEPOD findingsM Okera, S Chan, U Dernede, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 25, 2016
Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upS Novello, F Barlesi, R Califano, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 29, 2020
Correction to: "Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up"D Planchard, S Popat, K Kerr, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 5, 2018
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upD Planchard, S Popat, K Kerr, et al.
European Journal of Cancer (Oxford, England : 1990)|November 29, 2011
A phase II study of ¹⁸F-fluorodeoxyglucose PET-CT in non-small cell lung cancer patients receiving erlotinib (Tarceva); objective and symptomatic responses at 6 and 12 weeksM E R O'Brien, J S Myerson, J I G Coward, et al.
BMJ Open Respiratory Research|January 2, 2015
An unblinded, randomised phase II study of platinum-based chemotherapy with vitamin B12 and folic acid supplementation in the treatment of lung cancer with plasma homocysteine blood levels as a biomarker of severe neutropenic toxicityA R Minchom, K Saksornchai, J Bhosle, et al.
Lung Cancer (Amsterdam, Netherlands)|November 20, 2024
Lorlatinib-associated weight gain and dyslipidaemia: A retrospective analysis and implications for future careA John, D J McMahon, D Chauhan, et al.
Lung Cancer (Amsterdam, Netherlands)|April 3, 2024
Familial rare EGFR-mutant lung cancer syndrome: Review of literature and description of R776H familyL Gabriel, T McVeigh, S Macmahon, et al.
ESMO Open|June 30, 2023
Ramucirumab plus erlotinib versus placebo plus erlotinib in previously untreated EGFR-mutated metastatic non-small-cell lung cancer (RELAY): exploratory analysis of next-generation sequencing resultsE B Garon, M Reck, K Nishio, et al.
Pageof 9